“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Currency in NZD
Last close As at 09/06/2023
NZD3.74
▲ −0.16 (−4.10%)
Market capitalisation
NZD392m
AFT Pharmaceuticals is a specialty pharmaceutical company that operates primarily in Australasia but has product distribution agreements across the globe. The company’s product portfolio includes prescription and over-the-counter (OTC) drugs to treat a range of conditions and a proprietary nebuliser.
AFT is a multi-product company targeting pharmacy prescription, OTC and hospital markets. Data for Maxigesic offer it a competitive advantage in a fragmented industry.
Managing Director - Head of Content, Healthcare
David Flacks
Chairman
Dr Hartley Atkinson
CEO
Malcolm Tubby
Chief Financial Officer
Michael Weinmann
Member of the Board of Directors
Nathan D. Hukill
Member of the Board of Directors
Forecast net debt (NZ$m)
28.2
Forecast gearing ratio (%)
32
| % | 1M | 3M | 12M |
|---|---|---|---|
| Actual | 13.3 | 2.8 | (9.0) |
| Relative | 15.8 | 5.0 | (9.8) |
| 52 week high/low | 4.1/3.2 |
AFT Pharmaceuticals is a profitable New Zealand-based specialty pharmaceutical company that sells 130 proprietary branded and generic products through its own salesforce in New Zealand and Australia, with offices in SE Asia and Europe to handle its growing export business. Among its strategic priorities for FY23, Maxigesic remains the main commercial driver with plans to launch new variants internationally, including Maxigesic IV in the US, for which the FDA has set a PDUFA date of 17 October 2023, post AFT’s submission of additional requested data in April 2023. Other recent developments include the FDA approval for Maxigesic Rapid tablets (marking AFT’s first entry into the high-margin US market) and approval of Crystawash Extend by China’s National Medical Products Administration. Despite its revised guidance in November 2022, AFT remains on track to pay a maiden dividend at the end of FY23.
| Y/E Mar | Revenue (NZ$m) | EBITDA (NZ$m) | PBT (NZ$m) | EPS (c) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2022A | 130.3 | 21.4 | 18.9 | 19.2 | 19.5 | 31.9 |
| 2023A | 156.6 | 21.4 | 16.7 | 11.0 | 34.0 | 37.9 |
| 2024E | 184.0 | 25.2 | 21.7 | 15.2 | 24.6 | 21.9 |
| 2025E | 214.0 | 42.7 | 39.4 | 27.3 | 13.7 | 11.6 |
Get access to the very latest content matched to your personal investment style.
